- Home
- PULM vs OCEA Comparison
PULM vs OCEA Comparison
Compare PULM & OCEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PULM
- OCEA
- Stock Information
- Founded
- PULM 2003
- OCEA 2019
- Country
- PULM United States
- OCEA United States
- Employees
- PULM N/A
- OCEA N/A
- Industry
- PULM Biotechnology: Pharmaceutical Preparations
- OCEA Biotechnology: Pharmaceutical Preparations
- Sector
- PULM Health Care
- OCEA Health Care
- Exchange
- PULM Nasdaq
- OCEA Nasdaq
- Market Cap
- PULM 21.0M
- OCEA 20.5M
- IPO Year
- PULM N/A
- OCEA N/A
- Fundamental
- Price
- PULM $6.11
- OCEA $0.47
- Analyst Decision
- PULM
- OCEA
- Analyst Count
- PULM 0
- OCEA 0
- Target Price
- PULM N/A
- OCEA N/A
- AVG Volume (30 Days)
- PULM 40.5K
- OCEA 631.6K
- Earning Date
- PULM 11-08-2024
- OCEA 01-13-2025
- Dividend Yield
- PULM N/A
- OCEA N/A
- EPS Growth
- PULM N/A
- OCEA N/A
- EPS
- PULM N/A
- OCEA N/A
- Revenue
- PULM $10,005,000.00
- OCEA N/A
- Revenue This Year
- PULM N/A
- OCEA N/A
- Revenue Next Year
- PULM $1.00
- OCEA N/A
- P/E Ratio
- PULM N/A
- OCEA N/A
- Revenue Growth
- PULM 47.05
- OCEA N/A
- 52 Week Low
- PULM $1.55
- OCEA $0.43
- 52 Week High
- PULM $8.44
- OCEA $7.79
- Technical
- Relative Strength Index (RSI)
- PULM 51.10
- OCEA 34.89
- Support Level
- PULM $5.95
- OCEA $0.53
- Resistance Level
- PULM $6.30
- OCEA $0.70
- Average True Range (ATR)
- PULM 0.43
- OCEA 0.08
- MACD
- PULM -0.10
- OCEA -0.02
- Stochastic Oscillator
- PULM 11.86
- OCEA 10.28
About PULM Pulmatrix Inc.
Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.
About OCEA Ocean Biomedical Inc.
Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.